 |
|
National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003
Randall S. Stafford, MD, PhD;
Rebecca L. Drieling, BA;
Adam L. Hersh, MD, PhD
Arch Intern Med. 2004;164:1525-1530.
Background Research is limited on physicians' prescribing practices for osteoporosis treatment. We investigated patterns of pharmacotherapy from 1988 to 2003 and the impact of new medications on identification and treatment of patients with osteoporosis.
Methods We tracked trends from 1988 through 2003 in the frequency of osteoporosis visits and patterns of pharmacotherapy associated with these visits using nationally representative data on prescribing patterns by office-based US physicians from the IMS HEALTH National Disease and Therapeutic Index.
Results The number of physician visits for osteoporosis increased 4-fold between 1994 (1.3 million visits) and 2003 (6.3 million visits), whereas it had remained stable in prior years. This increase coincided with the availability of oral daily bisphosphonates and the selective estrogen receptor modulator raloxifene. The annualized percentage of osteoporosis visits where medications were prescribed increased from 82% in 1988 to 97% by 2003. Prior to 1994, the leading choices for osteoporosis therapy were calcium and estrogens, with lesser roles played by calcitonins and bisphosphonates. Between 1994 and 2003, the percentage of visits where bisphosphonates and raloxifene were prescribed increased from 14% to 73% and from 0% to 12%, respectively, while prescriptions for other medications declined.
Conclusions New medications for osteoporosis offering improved efficacy and convenient dosing were associated with increased frequency of patient visits and treatment. This finding suggests that new drug therapy contributed to increased disease recognition and treatment.
From the Stanford Prevention Research Center, Stanford University, Palo Alto, Calif. The authors have no relevant financial interest in this article.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
Undertreatment of Osteoporosis in Men
Arch Intern Med. 2005;165(2):241.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015
Sedjo et al.
CA Cancer J Clin 2007;57:326-340.
ABSTRACT
| FULL TEXT
Possible Increase in Liver Enzymes Secondary to Atorvastatin and Black Cohosh Administration
Patel and Derkits
Journal of Pharmacy Practice 2007;20:341-346.
ABSTRACT
Americans are not meeting current calcium recommendations
Ma et al.
Am. J. Clin. Nutr. 2007;85:1361-1366.
ABSTRACT
| FULL TEXT
Serum retinyl esters are not elevated in postmenopausal women with and without osteoporosis whose preformed vitamin A intakes are high
Penniston et al.
Am. J. Clin. Nutr. 2006;84:1350-1356.
ABSTRACT
| FULL TEXT
Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis.
Nayak et al.
ANN INTERN MED 2006;144:832-841.
ABSTRACT
| FULL TEXT
Undertreatment of Osteoporosis in Men
Arch Intern Med 2005;165:241-241.
FULL TEXT
|
